 {% extends "layout.html" %}

{% block title %}Human Practices{% endblock %}
{% block lead %}{% endblock %}



{% block page_content %}

<div class="education-hero hp-banner">
  <div class="education-hero-content-container">
    <h1 class="text-glitch">HUMAN PRACTICES</h1>
  </div>
</div>

<div class="spacer5"></div>


<div class="page-section width-75" id="intro">

  <div class="section-title ">
    <h1 style="text-align: left;" class="animate-text-scramble">Introduction</h1>
  </div>

  <p style="text-align: left;">In our Integrated Human Practices, our goal was to identify and learn
    from the stakeholders
    most central to our project. We approached this from multiple angles: <strong> tracing the creators of core
      protocols,
      papers, and patents for <italic>K. phaffii</italic>; reaching out to founders of emerging biotech and food-tech
      startups; consulting
      those with first-hand experience of pitfalls we anticipated, from DSP bottlenecks to failed ventures; and
      engaging
      with large protein purification companies and VCs who have seen many ideas like ours and know the common
      mistakes
    </strong>.
    <br><br>
    <strong> Domain expert input</strong> became <strong>crucial</strong> for our <strong>DBTL cycles</strong> when
    <strong>unresolved complexities</strong> or ambiguities <strong>arose during
      investigation</strong> of information available in the public domain.
    <br><br>
    Through this process, we developed not just scientific knowledge, but a <strong>deep industrial
      understanding</strong> of precision
    fermentation, strain engineering, protein manufacturing in yeast, and the challenging regulatory and investment
    landscape of alternative proteins. <strong>This became our team’s unique edge</strong> , and the key conversations
    that shaped us
    are highlighted in the timeline below, as they fundamentally changed our direction at critical moments.
    <br><br>
    <br><br>
    Use the <i>quick links</i> below to discover the phases of our journey:
  </p>


  <div class="spacer5"></div>


  <div>

    <p style="text-align: center;">
      <a class="text-glitch" href="#project-planning"><strong>IDEATION</strong></a>
      <img src="https://static.igem.wiki/teams/5916/assets/icons/arrow3.webp" alt="separator icon"
        class="icon-separator">
      <a class="text-glitch" href="#research-and-experimentation"><strong>RESEARCH</strong></a>
      <img src="https://static.igem.wiki/teams/5916/assets/icons/arrow3.webp" alt="separator icon"
        class="icon-separator">
      <a class="text-glitch" href="#downstream-and-implementation"><strong>DOWNSTREAM PROCESSING</strong></a>
      <img src="https://static.igem.wiki/teams/5916/assets/icons/arrow3.webp" alt="separator icon"
        class="icon-separator">
      <a class="text-glitch" href="#entrepreneurship-and-translation"><strong>FINANCE/FUNDING</strong></a>
    </p>
  </div>


</div>



<div class="spacer5"></div>


<div class="page-section width-75">

  <p style="text-align: left;">Or use the <i>timeline</i> below to follow our journey in chronological order:</p>

</div>



<div class="spacer5"></div>


<div class="people-timeline">
  <div class="timeline-line"></div>
  <div class="timeline-row timeline-row-top">
    <div class="timeline-item no-icon"><a href="#lisa-neidhardt-oliver-konzock">
        <div class="timeline-name">Dr. Lisa Neidhardt<br>& Dr. Oliver Konzock</div>
      </a></div>
    <div class="timeline-item"><a href="#jason-yu">
        <div class="timeline-name"><strong>Dr. Jason Yu</strong></div>
        <div class="timeline-icon"><img class="tilt-effect"
            src="https://static.igem.wiki/teams/5916/assets/images/team/jason.webp" alt="Dr. Jason Yu"></div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#martin-carballo-pacheco">
        <div class="timeline-name">Martin Carballo Pacheco</div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#ruben-perez-carrasco">
        <div class="timeline-name">Dr. Ruben Perez-Carrasco</div>
      </a></div>
    <div class="timeline-item"><a href="#mark-warner">
        <div class="timeline-name"><strong>Mark Warner</strong></div>
        <div class="timeline-icon"><img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/mark1.webp"
            alt="Mark Warner"></div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#noah-sprent">
        <div class="timeline-name">Dr. Noah Sprent</div>
      </a></div>
    <div class="timeline-item"><a href="#brigitte-gasser">
        <div class="timeline-name"><strong>Dr. Brigitte Gasser</strong></div>
        <div class="timeline-icon"><img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/brigitte1.webp"
            alt="Dr. Brigitte Gasser"></div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#victoria-faber">
        <div class="timeline-name">Victoria Faber</div>
      </a></div>
    <div class="timeline-item"><a href="#nelli-morgulchik">
        <div class="timeline-name"><strong>Nelli Morgulchik</strong></div>
        <div class="timeline-icon"><img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/nelli1.webp"
            alt="Nelli Morgulchik"></div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#hugh-bowen">
        <div class="timeline-name">Hugh Bowen</div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#sara-holland">
        <div class="timeline-name">Sara Holland</div>
      </a></div>
  </div>
  <div class="timeline-row timeline-row-bottom">
    <div class="timeline-item"><a href="#alexander-van-de-steen">
        <div class="timeline-icon"><img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/alex1.webp"
            alt="Dr. Alexander Van De Steen"></div>
        <div class="timeline-name"><strong>Dr. Alexander</strong><br><strong>Van De Steen</strong></div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#reka-tron">
        <div class="timeline-name">Reka Tron</div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#matthieu-bultelle">
        <div class="timeline-name">Matthieu Bultelle</div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#konstantin-pildish">
        <div class="timeline-name">Konstantin Pildish</div>
      </a></div>
    <div class="timeline-item"><a href="#martina-miotto">
        <div class="timeline-icon"><img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/martina.webp"
            alt="Martina Miotto"></div>
        <div class="timeline-name"><strong>Martina Miotto</strong></div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#sam-prudence">
        <div class="timeline-name">Dr. Sam Prudence</div>
      </a></div>
    <div class="timeline-item"><a href="#magnify-bio">
        <div class="timeline-icon"><img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/stealth.webp"
            alt="Magnify Bio"></div>
        <div class="timeline-name"><strong>Magnify Bio</strong></div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#olivia-brown">
        <div class="timeline-name">Olivia Brown</div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#pedro-lovatt-garcia">
        <div class="timeline-name">Pedro Lovatt Garcia</div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#katie-moruzzi">
        <div class="timeline-name">Katie Moruzzi</div>
      </a></div>
  </div>
</div>

<div class="spacer5"></div>

<div class="snake-timeline">

  <div class="timeline-section-header" id="project-planning">

    <h3 class="tagline-subline">Project Planning</h3>

  </div>

  <div id="lisa-neidhardt-oliver-konzock" class="two-column-container timeline-event">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">


        <div class="tagline-subline" style="text-align: center; margin-bottom: 0;">
          <span class="animate-text-scramble">Dr. Lisa Neidhardt &</span>
        </div>
        <div class="tagline-subline" style="text-align: center; margin-top: -1rem;">
          <span class="animate-text-scramble">Dr. Oliver Konzock</span>
        </div>


        <div class="two-column-container">
          <div class="column-left">
            <div class="image-aligner-left"><img class="tilt-effect"
                src="https://static.igem.wiki/teams/5916/hp/lisa.webp" style="max-width: 100%;"></div>
          </div>
          <div class="column-right">
            <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/oliver.webp" style="max-width: 100%;">
          </div>
        </div>


      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">

        <div class="spacer5"></div>

        <p style="text-align: left;"> Early in our ideation phase, we consulted with Dr. Lisa Neidhardt and Dr. Oliver
          Konzock, both Postdoctoral Researchers at the Rodrigo Ledesma-Amaro lab with experience in yeasts such as
          <i>Yarrowia lipolytica</i> and <i>Saccharomyces cerevisiae</i>.
        </p>

        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left  ">

          <ul>
            <li style="text-align:left;">Aimed to identify the <strong>most suitable yeast chassis</strong> and framing
              for our <strong>alternative protein project.</strong></li>
            <div class="spacer"></div>
            <li style="text-align:left;">Learned about <strong>regulatory challenges</strong> and the importance of
              <strong>GRAS status</strong> in accelerating approval.
            </li>
            <div class="spacer"></div>
            <li style="text-align:left;">Focused on <strong>cultivated meat</strong> and <strong>recombinant growth
                factor production</strong> as key cost barriers in the field.</li>
            <div class="spacer"></div>
            <li style="text-align:left;">Determined that <em>Y. lipolytica</em> was <strong>too slow</strong> for iGEM
              timelines, leading to a pivot toward <em>K. phaffii.</em></li>
          </ul>

        </div>



        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">


          <p style="text-align:left ;"> We initially met with <strong>Dr. Lisa Neidhardt</strong>, a member of the <strong>Bezos Centre for Sustainable Protein</strong>
          and regional mentor for the <strong>Good Food Institute</strong>, to discuss how to frame our project so that it
          contributes meaningfully to the <strong>alternative protein field</strong>.
          <br><br>
          Dr. Neidhardt highlighted the inefficiencies of traditional food production — for instance, the 8:1 calorie
          conversion ratio for chicken — and shared examples of emerging sustainable protein ventures. She also drew
          attention to the <strong>regulatory burdens</strong> slowing down translation to market, emphasising that GRAS
          status can significantly accelerate approval.
          <br><br>
          Following this meeting, we decided to focus on <strong>cultivated meat</strong> — a promising but
          underexplored area of alternative proteins. Reports shared by Dr. Neidhardt identified <strong>recombinant growth factors</strong>
          as one of the main cost drivers in the field, guiding us to position our project as a solution to this
          specific bottleneck.
        </p>

        <div class="spacer"></div>

        <p style="text-align:left;">
          Our follow-up discussion with <strong>Dr. Oliver Konzock</strong> centred on microbial chassis selection.  
          He explained the design and transformation cycle of <em>Y. lipolytica</em>, noting that its slow growth and
          non-standard DNA parts would make it impractical within the iGEM timeline, where a single DBTL cycle could take
          over a month.  
          Drawing on his experience as a two-time iGEM team leader at TU Braunschweig, he advised us to
          design a project that would remain <strong>communicable to the public and feasible for students</strong>.
          <br><br>
          Following his advice, we explored <em>Komagataella phaffii</em> as a faster-cycling yeast with higher
          secretion efficiency and more industrial relevance.  
          <strong>Dr. Neidhardt and Dr. Konzock’s guidance</strong> gave us the clarity to focus our wet-lab strategy on
          a chassis that would remain time-resilient and scalable.  
          Both continued as project advisors throughout our journey.
        </p>
          <div class="collapsible-close">Close</div>
        </div>
      </div>
    </div>
  </div>

  <div class="spacer5"></div>

  <div id="alexander-van-de-steen" class="two-column-container timeline-event">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">

        <div class="tagline-subline " style="text-align: center;"><span class="animate-text-scramble">Dr. Alexander Van
            de
            Steen</span></div>
        <div class="image-aligner-center"> <img class="tilt-effect"
            src="https://static.igem.wiki/teams/5916/hp/alex1.webp" style="max-width: 70%;"></div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">

        <div class="spacer5"></div>

        <p style="text-align: left;"> Continuing our chassis selection process, we met with Dr. Alex Van de Steen, a
          postdoctoral researcher with
          expertise in <i>K. Phaffii</i>. This consultation aimed to clarify the practical timelines associated
          with <i>K. Phaffii</i> engineering and to evaluate whether it was the most strategic choice for our project
          goals</p>

        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left  ">


          <ul>
            <li style="text-align:left;">Wanted to assess the <strong>practicality</strong> and <strong>strategic
                fit</strong> of <em>K. phaffii</em> as our project's chassis.</li>
            <div class="spacer"></div>
            <li style="text-align:left;">Learned that <em>K. phaffii</em> can achieve <strong>sub-month transformation
                cycles</strong> and offers <strong>strong secretion capacity.</strong></li>
            <div class="spacer"></div>
            <li style="text-align:left;">Confirmed its advantages for <strong>high-yield protein production</strong>
              aligned with our goals.</li>
            <div class="spacer"></div>
            <li style="text-align:left;">Received <strong>validation</strong> and continued <strong>advisory
                support</strong> on experimental design and troubleshooting throughout the project.</li>
          </ul>

        </div>



        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">

          <p style="text-align: left;"> <strong>Dr. Van de Steen</strong> confirmed that <em>K. phaffii</em> transformation cycles can be compressed
          to under one month and, with optimisation, may approach the speed of <em>S. cerevisiae</em>.  
          However, he cautioned that unless our project specifically required <em>K. phaffii’s</em> strengths — such as
          <strong>high volumetric protein yield, absence of self-inhibition, or superior secretion capacity and chaperone
          availability</strong> — there would be no inherent advantage over faster or better-characterised organisms like
          <em>E. coli</em>.
          <br><br>
          Because our goal was to leverage <strong>K. phaffii’s secretion abilities for growth factor production</strong>,
          this conversation gave us the <strong>confidence to move forward with it as our chassis of choice</strong>.
          We later consulted Dr. Van de Steen again for feedback on our final experimental plan before ordering parts,
          where he referred us to <strong>Dr. Jason Yu</strong> regarding CRISPR design specifics but approved our cloning
          and analytical methods.  
          He continued advising us throughout troubleshooting in the shared laboratory spaces.
          </p>
          <div class="collapsible-close">Close</div>
        </div>
      </div>
    </div>
  </div>

  <div class="spacer5"></div>


  <div class="timeline-section-header header-grey" id="research-and-experimentation">

    <h3 class="tagline-subline">Research and Experimentation</h3>
  </div>

  <div class="timeline-section-header header-grey" id="pichia-engineering">

    <h3 class="tagline-subline">K. Phaffii Engineering</h3>

  </div>

  <div id="brigitte-gasser" class="two-column-container timeline-event timeline-event-grey">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">

        <div class="tagline-subline " style="text-align: center;"><span class="animate-text-scramble">Dr. Brigitte
            Gasser</span></div>
        <div class="image-aligner-center"> <img class="tilt-effect"
            src="https://static.igem.wiki/teams/5916/hp/brigitte1.webp" style="max-width: 70%;"></div>
      </div>
    </div>
    <div class="column-right">

      <div class="timeline-content">
        <div class="spacer5"></div>
        <p style="text-align: left;">Dr Brigitte Gasser is an associate professor for microbial systems biotechnology
          and leader of sustainable production at the Austrian Centre of Industrial Biotechnology at BOKU University in
          Vienna. Her expertise broadly spans systems and synthetic biology for <i>K. phaffii</i> engineering, where she
          holds 20 patent families and serves on the editorial board of FEMS yeast research.
          <br><br>
        </p>

        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left  ">


          <ul>
            <li style="text-align:left; color: white;">Aimed to get insights from a <strong>leading academic</strong>
              with <strong>pioneering patent discovery.</strong></li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Obtained <strong>opposing perspectives</strong> on the importance
              of mannan impurities.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Decided <strong>against focusing</strong> on folding and cellular
              stress responses.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Discovered <strong>new stakeholder</strong> in pharmaceutical
              manufacturing.</li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">

          <p style="text-align: left;"> We reached out to <strong>Dr. Gasser</strong> to gain an expert perspective on the current frontiers of
          <em>K. phaffii</em> chassis improvement — particularly in <strong>metabolic engineering,
          folding, and stress-response pathways</strong>.  
          <br><br>
          When asked about industry concerns over <strong>polymannose contamination</strong> in high-cell-density
          cultures, she noted that this was **not yet a major issue raised by industry**, although academic work has
          begun exploring its effect on yield and purification. She confirmed that streamlining sugar metabolism remains
          a promising route for improving titres.
          <br><br>
          Dr. Gasser also pointed out bottlenecks in producing heterologous proteins with multiple disulfide bonds,
          which can lead to <strong>ER-associated degradation or cell lysis</strong>. While overexpressing UPR proteins
          or chaperones can sometimes mitigate this, she explained that such strategies rely on combinatorial tuning and
          are rarely generalisable — leading us to deprioritise this avenue for iGEM’s scope.
          <br><br>
          On fermentation, she described how most industrial <em>K. phaffii</em> processes still rely on
          <strong>fed-batch methanol systems</strong> but that continuous fermentation using other feedstocks such as
          glucose is gaining attention. Although we could not test this experimentally, this insight informed our
          understanding of future <em>K. phaffii</em> bioprocess design directions.
          <br><br>
          Finally, Dr. Gasser mentioned emerging initiatives — such as grants targeting “$10 per kg” monoclonal antibody
          production from the Bill & Melinda Gates Foundation — that motivate cost reduction for complex
          protein production. This highlighted new potential beneficiaries of a more efficient <em>K. phaffii</em>
          chassis, beyond cultivated meat applications.
          </p>
          <div class="collapsible-close collapsible-close-grey">Close</div>
        </div>

      </div>
    </div>
  </div>


  <div id="sam-prudence" class="two-column-container timeline-event timeline-event-grey" style="margin-top: -1%;">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">
        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Dr. Sam
            Prudence</span>
        </div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/sam.webp" style="max-width: 70%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>

        <p style="text-align: left;">Dr. Samuel Prudence is a senior research fellow at the University of Canterbury in
          New Zealand. His current work involves strain engineering of filamentous fungi to produce compounds that
          inhibit methane gas production in ruminants.
          <br><br>
        </p>

        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">

          <ul>
            <li style="text-align:left; color: white;">Aimed at understanding <strong>industrial yeast strain
                engineering challenges</strong> better.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Confirmed <strong>industrial advantages</strong> of <em>K.
                phaffii</em> compared to other hosts.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;"><strong>Discovered a hostile patent landscape</strong>
              surrounding yeast strain engineering.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Begun a new strategic mission of <strong>advocating for open
                source principles.</strong></li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">

          <p style="text-align: left;"> We reached out to <strong>Dr. Prudence</strong> during his time at <strong>Better Dairy</strong> to better
          understand the challenges faced by startups developing commercial yeast strains under industrial constraints.
          <br><br>
          He emphasised a key obstacle: the <strong>crowded and restrictive IP landscape</strong> surrounding
          industrially useful yeast strains.  
          Many strains are protected by commercial licences held by large contract manufacturers, leaving startups that
          cannot afford licensing at a disadvantage.  
          This reinforced our later interest in **open-license strain development** and transparency in strain
          characterisation.
          <br><br>We reached out to <strong>Dr. Prudence</strong> during his time at <strong>Better Dairy</strong> to better
          understand the challenges faced by startups developing commercial yeast strains under industrial constraints.
          <br><br>
          He emphasised a key obstacle: the <strong>crowded and restrictive IP landscape</strong> surrounding
          industrially useful yeast strains.  
          Many strains are protected by commercial licences held by large contract manufacturers, leaving startups that
          cannot afford licensing at a disadvantage.  
          This reinforced our later interest in **open-license strain development** and transparency in strain
          characterisation.
          <br><br>
          Dr. Prudence also discussed the **tension between venture capital timelines and scientific progress**.
          Companies are often expected to generate revenue while still scaling up operations, widening what he called
          the “valley of death” for biotech ventures.  
          He advised that the best strategy is to develop **revenue-generating components within a university context**
          before spinning out — a model we found particularly relevant to iGEM teams.
          <br><br>
          We also discussed **downstream processing bottlenecks**, which he identified as a major scaling barrier in the
          UK due to a lack of affordable, food-grade biomanufacturing facilities.  
          This echoed concerns from later consultations, showing that even well-engineered strains cannot succeed
          without appropriate industrial infrastructure.
          </p>
          <div class="collapsible-close collapsible-close-grey">Close</div>
        </div>

      </div>

    </div>





  </div>



  <div class="timeline-section-header header-grey" id="recombinant-protein-expression">
    <div class="tagline-subline"><span>Recombinant Protein Expression</span></div>
  </div>

  <div id="reka-tron" class="two-column-container timeline-event timeline-event-grey">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">

        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Reka Tron</span>
        </div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/reka1.webp" style="max-width: 70%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>


        <p style="text-align: left;">Very early on in our journey, we met with Reka Tron, former COO at Multus, a
          media optimisation company catering to the cultured meat sector. Reka has overseen operations ranging from
          regulatory compliance and procurement to long term-strategy during her five years at Multus.</p>

        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">

          <ul>
            <li style="text-align:left; color: #ffffff;">Wanted to figure out what the cultivated meat market's
              <strong>biggest
                needs</strong> are.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: #ffffff;">Settled on producing <strong>FGF2, IGF, EGF and HGF</strong>
              and strategies to
              <strong>express</strong> them.
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color: #ffffff;">Adopted strategies in education that better highlight
              <strong>challenges</strong> in public and industry <strong>perception</strong> of cultivated meat.
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color: #ffffff;">Decided against <strong>protein engineering</strong> for growth
              factors.</li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">

          <p style="text-align: left;">Our focus was understanding the <strong>key challenges in industrial <em>K. phaffii</em> applications</strong> and
          the broader landscape of cultivated meat media companies.  
          <br><br>
          Reka shared her experience overseeing growth factor production pipelines and validated our emphasis on
          <strong>IGF-1, EGF, and HGF</strong> as high-demand targets in cultivated meat.  
          She noted that while <strong>IGF-1 and EGF</strong> are smaller and easier to express, <strong>HGF</strong> poses
          significant difficulties due to its complex multi-chain structure and susceptibility to cleavage.  
          She recommended we include <strong>FGF2</strong> as an easier, more stable target with strong industrial
          relevance — advice that shaped our final experimental design.
          <br><br>
          Reka also discussed her previous company’s work in <strong>engineering growth factors for improved
          dose-response properties</strong>, showing us an alternate approach to reducing production costs.  
          However, given our focus on <strong>strain engineering and bioprocess design</strong>, we decided not to pursue
          protein modification within the iGEM timeframe.
          <br><br>
          The second part of our conversation turned to <strong>industry and public perception</strong>.  
          Reka explained that attention within the sector is shifting towards <strong>media composition and sustainability</strong>,
          with increasing interest in waste-derived carbon sources.  
          At the same time, she noted a growing public fatigue and investor caution towards alternative proteins — a
          realism that encouraged us to tailor our outreach and educational materials to address these perceptions more
          directly.
          <br><br>
          Overall, her insights helped us balance ambition with practicality, refine our target protein list, and
          develop a grounded communication strategy aligned with the current state of the industry.
          </p>
          <div class="collapsible-close collapsible-close-grey">Close</div>
        </div>
      </div>
    </div>






  </div>

  <div class="timeline-section-header header-grey" id="wet-lab">
    <div class="tagline-subline"><span>Wet Lab</span></div>
  </div>

  <div id="jason-yu" class="two-column-container timeline-event timeline-event-grey">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">
        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Dr. Jason Yu</span>
        </div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/assets/images/team/jason.webp"
            style="max-width: 70%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>

        <p style="text-align: left;">Dr Jason Yu is a member of the Polizzi lab in the Department of Chemical
          Engineering. His current research is centred on CRISPR-Cas9 engineering to change flocculation behaviour in
          <i>K. phaffii</i>, with applications in the cultivated meat industry. His expertise was fundamental in
          defining our
          engineering strategy and experimental workflow.
        </p>


        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">


          <ul>
            <li style="text-align:left; color:#ffffff">Aimed to validate <strong>CRISPR-Cas9</strong> design and
              workflow for <em>K.
                phaffii</em> <strong>engineering</strong></li>
            <div class="spacer"></div>
            <li style="text-align:left; color:#ffffff">Decided against <strong>multiplexed edits</strong> due to
              metabolic and
              <strong>cell viability</strong> concerns
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color:#ffffff">Adjusted strategy to <strong>gene insertion</strong> with
              <strong>inducible
                promoters</strong> and targeted sgRNAs
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color:#ffffff">Included <strong>electroporation into workflow</strong>,
              significantly changing
              transformation strategy</li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">

          <p style="text-align: left;">We reached out to <strong>Dr. Yu</strong> to refine our CRISPR-Cas9 design strategy for
          <em>K. phaffii</em> and ensure our approach was viable within iGEM constraints.  
          At this stage, we had identified gene targets and designed initial sgRNAs with the goal of modifying Kozak
          sequences to tune expression levels.  
          After reviewing our plan, Dr. Yu advised us to **abandon multiplexed editing**, which could cause metabolic
          strain and reduce viability, and instead focus on **single edits with clear functional endpoints**.
          <br><br>
          Through multiple discussions, we pivoted toward **Cas9-mediated gene insertions under inducible promoters**
          rather than promoter modifications.  
          Dr. Yu also introduced us to a **ΔKu70 strain of <em>K. phaffii</em>**, which improves homologous recombination
          efficiency, and he kindly provided us with aliquots of this strain for our experiments.
          <br><br>
          One of the most impactful contributions was his recommendation to incorporate **electroporation** into our
          transformation workflow — a method none of us had previously used — which ultimately enabled successful DNA
          delivery and stable integration.  
          He also provided insights on **primer design** for integration verification and explained how to
          interpret ambiguous gel results for CRISPR construct validation.
          <br><br>
          Dr. Yu’s ongoing mentorship shaped both our wet lab execution and our understanding of how to translate
          genetic edits into industrially meaningful outcomes.  
          He continued advising us throughout the summer and was formally onboarded as a project advisor.
          </p>

        </div>
      </div>
    </div>
  </div>



  <div id="brandon-ma" class="two-column-container timeline-event timeline-event-grey" style="margin-top: -1%;">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">
        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Brandon Ma</span>
        </div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/brandon1.webp" style="max-width: 80%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>

        <p style="text-align: left;">We held two in-depth consultations with Brandon Ma, Senior Scientist and Co-Founder
          of Multus, to refine both our technical execution and project strategy in <italic>K. phaffii</italic>
          engineering. </p>

        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">

          <ul>
            <li style="text-align:left; color:#ffffff">Consulted on our <strong><em>K. phaffii</em> engineering
                strategy</strong> and
              its industrial <strong>feasibility</strong>.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color:#ffffff">Focused on validating <strong>reduced impurity
                production</strong> over
              immediate growth factor purification.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color:#ffffff">Added <strong>FGF2 to research design, prioritising</strong>
              <strong>smaller
                proteins</strong> with <strong>simpler PTMs</strong>.
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color:#ffffff">Added <strong>quick</strong> <em>K. phaffii</em>
              <strong>monitoring
                steps</strong> to <strong>validate experimental success.</strong>
            </li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">

          <p style="text-align: left;">From his experience pivoting away from <italic>K. phaffii</italic>-based growth
            factor production, Brandon highlighted the challenges
            of an overcrowded landscape, CMO (Contract Manufacturing Organization) dependencies, and patent
            restrictions,
            encouraging us to frame our proof-of-concept around reduced sugar production rather than immediate growth
            factor purification.
            <br><br>
            He also gave us plenty of advice for working with <italic>K. phaffii</italic>. He recommended beginning with
            the wild type
            CBS 7435 strain, using small constructs with ~80 ng DNA input, and screening over 100 clones via 96-well
            plates with dot blots for validation. We deemed this infeasible at iGEM scales and did not implement this
            for
            our project. He additionally shared practical troubleshooting tips, including monitoring pellet color and
            smell for contaminants, and using dual antibiotic selection.
            <br><br>
            For CRISPR design, Brandon advised manually validating primers against the <italic>K. phaffii</italic>
            genome using NCBI
            files, ordering multiple primer sets, and sequencing bands when gels are inconclusive. He recommended
            specific
            software for codon optimization and suggested ordering multiple optimized variants to compare expression.
            <br><br>
            In terms of targets, he advised us to prioritize EGF and IGF due to their higher stability. Brandon raised
            some concerns against our plan to focus on HGF production, since the 3-balls-on-a-chain structure is prone
            to
            cleavage. He suggested producing FGF2, a smaller, more stable protein. Consequently, we introduced FGF2 as a
            more feasible target protein alongside HGF for confirmation of our rPOI expression workflow.
          </p>
          <div class="collapsible-close collapsible-close-grey">Close</div>
        </div>
      </div>
    </div>
  </div>

  <div class="timeline-section-header header-grey" id="dry-lab">
    <div class="tagline-subline"><span>Dry Lab</span></div>
  </div>

  <div id="ruben-perez-carrasco" class="two-column-container timeline-event timeline-event-grey">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">

        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Dr. Ruben
            Perez-Carrasco</span></div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/ruben.webp" style="max-width: 70%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>


        <p style="text-align: left;">We consulted Dr. Ruben Perez-Carrasco to refine our approach to Bayesian
          optimization for carotenoid pathway engineering. Specifically, we focused on techniques and approaches to
          dealing with biological noise that is intrinsic to synthetic biology wet lab experiments.</p>


        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">

          <ul>
            <li style="text-align:left; color: white;">Aimed to discuss <strong>Bayesian optimisation</strong> and
              handling <strong>biological noise.</strong></li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Prioritised <strong>synthetic datasets</strong> with
              <strong>simple ODEs</strong> and <strong>Gaussian noise as validation.</strong>
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;"><strong>Took up on key Bayesian inference</strong> tools for
              integrating experimental variables.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Redesigned laboratory procedures underpinning dry lab model
              validation.</li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">

          <p style="text-align: left;">
            To validate the method, he recommended creating a synthetic dataset with simple ODE outputs and Gaussian
            noise
            inputs before moving to more complex equations. Heteroscedastic noise should only be introduced and tested
            after sufficient model accuracy is confirmed with homoscedastic noise.
            <br><br>
            Regarding new tools, Ruben highlighted the PyMC library for Bayesian interference, which could be used to
            isolate the experimentally derived variables and reinsert them back into the model. This was tested as part
            of
            the optimisation stack.
            <br><br>
            As a response to our proposed experimental design, he stressed ensuring that cell cultures remain in the log
            growth phase, since overcrowding inherently changes the metabolic state of a cell. Finally, he provided key
            literature references, which all helped us to build our dry lab components.
          </p>
          <div class="collapsible-close collapsible-close-grey">Close</div>
        </div>
      </div>
    </div>
  </div>

  <div id="matthieu-bultelle" class="two-column-container timeline-event timeline-event-grey" style="margin-top: -1%;">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">

        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Dr. Matthieu
            Bultelle</span></div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/matthieu.webp" style="max-width: 70%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>


        <p style="text-align: left;">We consulted Dr. Bultelle for his expertise in replicable engineering-biology
          workflow design and its automation. His advice was vital for setting early goals and imposing a structure for
          the Bayesian optimization campaign of astaxanthin bioproduction experiments.</p>

        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">

          <ul>
            <li style="text-align:left; color: white;">Sought out suggestions for <strong>improvement of optimisation
                validation</strong> experiment.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;"><strong>Implemented focus on specific varying properties</strong>
              to reduce complexity.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Adjusted <strong>inducer handling</strong> for better
              <strong>accuracy</strong> and <strong>comparability</strong> across trials.
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Simplified <strong>workflows</strong> and focused on
              <strong>proof-of-concept validation.</strong>
            </li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">


          <p style="text-align: left;">
            Dr. Bultelle’s initial advice concerned repeatability and experimental variance. We were encouraged to vary
            stimulus and environmental properties while avoiding introduction of genetic variation. Introduced inducer
            concentration accuracy was raised as a significant issue when working with very small volumes. This led us
            to
            adopt the strategy of dispensing larger volumes and bulk preparation.
            <br><br>
            Lastly, we simplified our experimental design, leaning more heavily on established techniques and
            straightforward workflows. Dr. Bultelle’s advice against attempting to design our own automation protocol
            for
            the OpenTron in our lab on short notice led to us to place more value on our proof-of-concept experimen
          </p>
          <div class="collapsible-close collapsible-close-grey">Close</div>
        </div>
      </div>
    </div>
  </div>

  <div class="spacer3"></div>

  <div class="timeline-section-header" id="downstream-and-implementation">
    <div class="tagline-subline"><span>Downstream and Implementation</span></div>
  </div>

  <div class="timeline-section-header" id="industry-overall">
    <div class="tagline-subline"><span>Industry Overall</span></div>
  </div>


  <div id="mark-warner" class="two-column-container timeline-event">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">
        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Mark Warner</span>
        </div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/mark1.webp" style="max-width: 70%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>

        <p style="text-align: left;">Mark Warner is the CEO of Liberation Bioindustries, a leading large-scale contract
          manufacturer in Indiana, USA. He has consulted numerous high-profile startups and companies within the
          biomanufacturing, alternative food- and protein space. Our goal was to leverage his experience in the sector
          to gain a better understanding of industrial issues.</p>


        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">

          <ul>
            <li style="text-align:left;">Aimed to target <strong>industrial-scale biomanufacturing challenges.</strong>
            </li>
            <div class="spacer"></div>
            <li style="text-align:left;">Learnt about the <strong>perception gap</strong> between academic and
              industrial priorities.</li>
            <div class="spacer"></div>
            <li style="text-align:left;">Discovered that purification issues get comparatively <strong>less
                attention</strong> than yield-centric engineering.</li>
            <div class="spacer"></div>
            <li style="text-align:left;">Determined that <strong>market coordination failure</strong> is the most likely
              failure point of cultivated meat scaling right now.</li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">


          <p style="text-align: left;">
            The most striking takeaway from our conversation was the seemingly large amount of misconceptions
            surrounding best practice in biomanufacturing that persist in academia, such as specific titre quantities or
            comparative importance of chassis engineering vs downstream processing. Notably, there has been
            comparatively
            low interest from researchers in downstream processing improvements as opposed to yield-centric strain
            engineering. Largely, this seeming lack of information was attributed to differences in funding structures
            and
            a lack of incentives to share achievements from industry. As Mr. Warner pointed out, intellectual property
            and
            the pursuit of a competitive edge has allowed many industry-engineered strains to far surpass the current
            best estimates in academia.
            <br><br>
            This led us to critically examine a limitation of our project: the difficulty in benchmarking our strain
            engineering quantitatively, since the most comparative data are likely not publicly available. Consequently
            we
            constrained our focus more on our unique improvement avenues, like previously under-investigated impurities,
            rather than improving widely accepted performance objectives like space-time yield.
            <br><br>
            Mr. Warner expressed that a large amount of businesses in the novel foods sector likely fail due to blind
            spots in industrial contexts , justifying our contact with corporate bioprocessing experts. A common issue
            was focus on rPOI expression improvement taking attention away from needed and viable methods of
            purification.
            Drawing on experience, he flagged that there were likely currently no insurmountable hurdles to producing
            large volumes of growth factors in methanol-fed *K. phaffii*. Interestingly, this directly contradicted
            some
            input we had received previously about fundamental upstream issues blocking the viability of growth factor
            production at scale to meet demands of the cultivated meat industry.
            <br><br>
            It also partially confirmed our hypothesis that barriers in downstream processing, like lysis or impurities,
            would be a more useful objective to tackle. Based on Mr. Warner's
            recommendation, we contacted Blake Byrne
            and Dr. Christian Schuster at Magnify Bio which revealed specific downstream purification challenges to
            us.
            <br><br>
            Additionally, he emphasised that the existing cleanroom standards followed by most bioproduction plants are
            prohibitively expensive for scaling up food-grade protein production, highlighting the need for more
            large-scale facilities specifically designed for this purpose.
            <br><br>
            Seed-scale production companies of lower-cost growth factors for cultivated meat were driven by what Mr
            Warner
            called a “chicken and egg problem” that is fuelled by market uncertainty. In essence, synthetic meat
            companies seem not to scale due to a lack of affordable growth factors, while the lack of an active market
            discourages development in food-grade growth factor production. Our takeaway was that a successful
            cultured
            meat startup needs to have strong founding partnerships with suppliers and realistic demand forecasts to
            succeed.
            <br><br>
            While we couldn't address market structure issues through strain engineering alone, this conversation
            clarified why engaging with established contract manufacturers was more valuable than focusing exclusively
            on
            cultivated meat startups, as the former can provide grounded assessments of technical barriers rather than
            aspirational projections.
          </p>
          <div class="collapsible-close">Close</div>
        </div>
      </div>
    </div>
  </div>

  <div class="timeline-section-header" id="culturing">
    <div class="tagline-subline"><span>Culturing</span></div>
  </div>

  <div id="noah-sprent" class="two-column-container timeline-event">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">

        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Dr. Noah
            Sprent</span></div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/noah.webp" style="max-width: 70%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>


        <p style="text-align: left;">We contacted Dr. Noah Sprent, co-founder of ChangeBio, a startup focusing on
          industrial protein manufacturing innovation in <i>K. phaffii</i>, while planning our mini jamboree. We found
          an
          overlap in interest on fundamental, open contributions to support commercially viable <i>K. phaffii</i>
          applications.</p>


        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">


          <ul>
            <li style="text-align:left;">Aimed to validate our <em>K. phaffii</em> <strong>engineering approach</strong>
              and explored <strong>open, commercially viable</strong> strain development.</li>
            <div class="spacer"></div>
            <li style="text-align:left;">Added a new collaboration effort to characterise an <strong>open-source <em>K.
                  phaffii</em> strain.</strong></li>
            <div class="spacer"></div>
            <li style="text-align:left;">Designed a strategy to avoid CRISPR licensing issues through an alternative
              protocol.</li>
            <div class="spacer"></div>
            <li style="text-align:left;">Received access to a <strong>2L bioreactor</strong> necessary for industrial
              validation.</li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">



          <p style="text-align: left;">
            Our cell wall and mannose pathway targeting was validated as a potential blind spot in engineering of the
            Chassis, given the long running history of trHoc1 strains with little iteration. Dr. Sprent agreed on the
            essentiality of downstream processing efficiency gains, as well as the room for improvement present there.
            As
            this is the first year of <i>K. phaffii</i> being greenlit as a Chassis, we planned a collaboration to
            publish
            the
            whole genome sequence of a strain lacking commercial licensing issues or restrictions. This is part of an
            effort spearheaded by Dr. Sprent named PhaffiiNet, which aims to avoid the commercial red tape around <i>K.
              phaffii</i> strains that Dr. Sprent ran into commercial licensing limitations with.
            <br><br>
            He agreed to transfer the strain to us for validation purposes and thus support the development of <i>K.
              phaffii</i> as a commercial strain within iGEM.
            <br><br>
            Dr. Sprent generously offered us a 2L bioreactor to run a trial fermentation in, which would yield more
            industrially relevant results than shake flask cultures.
            <br><br>
            He also flagged issues of using CRISPR for commercial and industrial use cases due to licensing issues, and
            proposed the alternative of using a split marker double-crossover with a floxed episomal resistance marker.
            It
            was concluded that we could emulate our edits using this method if commercialisation was our goal, though by
            this point the strategy was not feasible as we had already followed through with our CRISPR recombination
            engineering.
            <br><br>
            Additionally, Dr. Sprent directed us towards several industry experts in <i>K. phaffii</i> manufacturing at
            scale,
            including Mark Warner and Blake Byrne, who we later reached out to.
          </p>
          <div class="collapsible-close">Close</div>
        </div>
      </div>
    </div>
  </div>



  <div class="timeline-section-header" id="scale-up-process-design">
    <div class="tagline-subline"><span>Scale-up/ Process Design</span></div>
  </div>


  <div id="martin-carballo-pacheco" class="two-column-container timeline-event">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">

        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Dr. Martin Carballo
            Pacheco</span></div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/martin.webp" style="max-width: 70%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>

        <p style="text-align: left;">Our team consulted with Dr. Martin Carballo Pacheco, a senior scientist at Hoxton
          Farms, a biotechnology company pioneering cultivated pork fat production. Hoxton farms focuses on cultivated
          pork fat and closely aligns with what would be an ideal partner for our business case. Martins expertise in
          technical bottlenecks, industry practices, and market factors was key for our perception of cultivated meat
          industry.</p>


        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">


          <ul>
            <li style="text-align:left;">Aimed to discuss the <strong>market relevance</strong> of our growth factor
              platform.</li>
            <div class="spacer"></div>
            <li style="text-align:left;">Validated assumptions on bottlenecks in the <strong>scarcity of suppliers for
                affordable growth factors</strong>.</li>
            <div class="spacer"></div>
            <li style="text-align:left;">Confirmed the <strong>integration of Bayesian optimisation</strong> into our
              modelling workflow.</li>
            <div class="spacer"></div>
            <li style="text-align:left;">Evaluated the <strong>techno-economic importance of growth factors.</strong>
            </li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">



          <p style="text-align: left;">
            Dr. Carballo Pacheco has helped us to understand the perspective of a cultivation-focused company,
            furthering
            our understanding of the demand-side concerns in the growth factor market. Key challenges to expansion were
            described as transition from research to commercial scale, expensive validation studies for stirred tank
            bioreactors, and lack of established market for bulk growth factors. Although growth factors are available
            on
            the milligram scale, finding suppliers that would produce kilogram-scale food-grade and low-cost growth
            factors remains an unsolved issue. Martin has also directed us towards a report from the
            Good Food Institute [1], which outlines that growth factors can contribute up to 90% of media cost.
            <br><br>
            This has confirmed our initial focus on growth factors for synthetic meat, but more importantly showed that
            projects financial success will be determined by matching a market need. This was further emphasized by
            Martin’s advice to partner with real world companies for validation of real world applications.
            <br><br>
            We also discussed Hoxton’s use of specific data science methods, namely Bayesian optimization, for rapid,
            small-scale media testing before scaling to pilot reactors. Specifically, the utility of transfer learning
            in
            Bayesian optimization for faster and lower experimental footprint scale-up optimization was confirmed. It
            validated our decision to a similar computational tools in our modelling workflow.
            <br><br>
            Finally, Martin was one of the key speakers for our Food Tech panel during the Mini Jamboree we hosted at
            Imperial College London. He delivered a well-received presentation about the science and hard work that
            makes
            cultivated pork fat a reality of today rather a dream of tomorrow. He also generously provided another round
            of feedback for our preliminary project pitch at the mini jamboree.
          </p>
          <div class="collapsible-close">Close</div>
        </div>
      </div>
    </div>
  </div>

  <div class="spacer10"></div>

  <div id="konstantin-pildish" class="two-column-container timeline-event">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">

        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Konstantin
            Pildish</span></div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/konstantin.webp" style="max-width: 70%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>


        <p style="text-align: left;">We met with Konstantin, a Purification Development Scientist at Lonza, to refine
          our protein purification strategy. His expertise in downstream bioprocessing and industrial-scale purification
          was particularly relevant to our use of <italic>K. phaffii</italic> for growth factor production in a
          food-grade context.</p>


        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">


          <ul>
            <li style="text-align:left;">Consulted on our <strong><em>K. phaffii</em> engineering strategy</strong> and
              its industrial <strong>feasibility</strong>.</li>
            <div class="spacer"></div>
            <li style="text-align:left;">Focused on validating <strong>reduced impurity production</strong> over
              immediate growth factor purification.</li>
            <div class="spacer"></div>
            <li style="text-align:left;">Added <strong>FGF2 to research design, prioritising</strong> <strong>smaller
                proteins</strong> with <strong>simpler PTMs</strong>.</li>
            <div class="spacer"></div>
            <li style="text-align:left;">Added <strong>quick</strong> <em>K. phaffii</em> <strong>monitoring
                steps</strong> to <strong>validate experimental success.</strong></li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">



          <p style="text-align: left;">
            <br><br>
            Konstantin confirmed that <italic>K. phaffii</italic> is a suitable chassis for food applications that
            require complex
            proteins but not necessarily humanised glycosylation. He explained that most growth factors fall below 1000
            amino acids, making purification more manageable, and that post-translational modifications are less
            critical
            in food than in therapeutic settings.
            <br><br>
            The consultation confirmed our choice of using His-tag affinity chromatography to purify and quantify our
            recombinant proteins, as we were told to avoid size exclusion chromatography due to some inefficiencies at
            large scale.
            <br><br>
            He also recommended reverse-phase chromatography as a low-cost alternative, especially for small, refoldable
            proteins. Konstantin further provided insight into realistic yields (0.5 g/L in <italic>K. phaffii</italic>)
            and scale-up
            strategies, advocating for 1000L single-use bioreactors and ISO 7 food-grade facilities, which reduce
            sterility and QA costs compared to pharmaceutical production.
          </p>
          <div class="collapsible-close">Close</div>
        </div>
      </div>
    </div>
  </div>

  <div class="spacer10"></div>

  <div id="magnify-bio" class="two-column-container timeline-event">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">

        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Magnify Bio</span>
        </div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/magnify.webp" style="max-width: 40%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>


        <p style="text-align: left;">
          We connected with Blake Byrne, the CEO of Magnify Bio and former technology analyst at the Good Food
          Institute through Mark Warner at Liberation Bioindustries. Mr. Warner referred us to them for their
          <strong>expertise in cutting-edge downstream recovery</strong> techniques for the broader bioeconomy. During
          our meeting, we also spoke with Magnify Bio's CTO, Dr. Christian Schuster.
        </p>



        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">


          <ul>
            <li style="text-align:left;">Aimed to assess <strong>downstream processing challenges</strong> in <em>K.
                phaffii.</em></li>
            <div class="spacer"></div>
            <li style="text-align:left;">Processing costs showed <strong>the potential financial savings</strong> our
              solution could deliver.</li>
            <div class="spacer"></div>
            <li style="text-align:left;"><strong>Polysaccharide contamination</strong> confirmed to affect purification
              feasibility.</li>
            <div class="spacer"></div>
            <li style="text-align:left;"><strong>Gaps identified in</strong> <strong>stakeholder mapping promptly solved
                via</strong> further interviews.</li>
          </ul>
        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">


          <p style="text-align: left;">
            Our goal was to <strong>gather their assessment of downstream processing issues</strong>, specifically in
            <em>K. phaffii</em>. Dr. Schuster confirmed that ongoing efforts to improve the chassis' processing
            properties are <strong>currently organised according to the different molecular properties</strong> of
            target proteins. We discussed <strong>polysaccharide contamination in the supernatant</strong> as being an
            issue of potential significance, particularly when <strong>contaminants appear in a similar mass
              band</strong> as the product being recovered and <strong>cannot be separated through ion
              exchange</strong>.
          </p>
          <div class="spacer"></div>
          <p style="text-align: left;">
            This <strong>validated our efforts in removing such impurities</strong>, however this is, by no means, a
            magic bullet. Certain protein properties (e.g. mass or charge) can negate the impurities' importance by
            making certain recovery techniques more feasible.
          </p>
          <div class="spacer"></div>
          <p style="text-align: left;">
            According to Dr. Schuster, <strong>purification costs in the broader biomanufacturing sector typically range
              from 20-80€ per kg</strong> of product at average purity levels. These <strong>costs increase
              significantly when</strong> there are higher levels of lysis and other contaminants, as <strong>additional
              unit processing steps become necessary</strong>. Higher expression does not always equal greater cost
            benefits as resulting cell lysis and metabolic byproducts can exacerbate purification costs. This
            <strong>disproportionate tradeoff can particularly affect companies</strong> in the novel bioeconomy trying
            to reach price parity with conventional alternatives.
          </p>
          <div class="spacer"></div>
          <p style="text-align: left;">
            This insight revealed a gap in our stakeholder mapping. We had focused our project primarily on complex
            growth factors, but hadn't considered that <strong>food proteins like recombinant casein may face the same
              purification cost challenges as growth factors</strong> while needing even lower final prices to compete
            with conventional dairy. We raised this directly with our supervisor Dr. Van de Steen, who is pursuing
            <strong>scale-up of recombinant milk proteins</strong>, where recovery costs may make or break commercial
            viability.
          </p>


          <div class="collapsible-close">Close</div>
        </div>
      </div>
    </div>
  </div>

  <div class="spacer3"></div>

  <div class="timeline-section-header header-grey" id="entrepreneurship-and-translation">
    <div class="tagline-subline"><span>Entrepreneurship and Translation </span></div>
  </div>



  <div class="timeline-section-header header-grey" id="vision-and-mission">
    <div class="tagline-subline"><span>Vision and Mission</span></div>
  </div>

  <div id="martina-miotto" class="two-column-container timeline-event timeline-event-grey">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">

        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Dr. Martina
            Miotto</span></div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/martina.webp" style="max-width: 80%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>



        <p style="text-align: left;">Dr. Martina Miotto is the cofounder of CellRev, a company that recently stopped
          trading
          . She shared her experience building a company that initially focused on cellular agriculture before
          ultimately pivoting toward pharma.</p>


        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">


          <ul>
            <li style="text-align:left; color: white;">Aimed to consult an <strong>ex-founder</strong> skeptic about
              cultivated meat's viability.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;"><strong>Realised how regulatory processes hinder</strong>
              FoodTech, costing companies' lifespans.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Advice on <strong>fast validation approached</strong> validated
              our pitch deck timeline.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;"><strong>Begun to emphasise FoodTech challenges</strong> in our
              iGEM outreach efforts.</li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">

          <p style="text-align: left;">
            Her journey highlighted both the promise and the pitfalls of the cultivated
            meat industry: despite developing a high-yield, continuous adherent cell manufacturing process and securing
            strong pharma trial partners, her team faced declining investment in cellular agriculture and long decision
            timelines after pivoting towards pharma, leading to the company’s closure. Martina emphasized the harsh
            realities of the current investment climate, overpromising by cultivated meat companies, waning investor
            confidence, and the particular difficulty of raising funds for enabling technologies rather than
            consumer-facing products. From this, she advised us to carefully balance diversification with focus, explore
            quicker market entry points, and prioritize revenue generation strategies such as non-dilutive funding and
            B2B-focused investors. Most importantly, she encouraged us to simplify our narrative for non-technical
            stakeholders and to critically evaluate the implementation challenges of our chosen market. Her candid
            reflections offered us invaluable perspective on both strategic pitfalls and resilience in biotech
            entrepreneurship, allowed us to highlight issues with the cultivated meat industry through our work, helping
            shape the way we frame Growf’s pathway to impact.
          </p>
          <div class="collapsible-close collapsible-close-grey">Close</div>
        </div>
      </div>
    </div>
  </div>


  <div class="timeline-section-header header-grey" id="business-strategy">
    <div class="tagline-subline"><span>Business Strategy</span></div>
  </div>


  <div id="victoria-faber" class="two-column-container timeline-event timeline-event-grey">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">

        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Victoria
            Faber</span></div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/victoria.webp" style="max-width: 70%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>



        <p style="text-align: left;">Early in our project, after we finished scientific ideation, we met with Victoria
          Faber, former Chief of Staff at Lightspeed Venture Partners & Angel Investor, to refine the strategic
          narrative behind our pitch deck.</p>


        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">


          <ul>
            <li style="text-align:left; color: white;">Consulted to refine the <strong>strategic narrative</strong> and
              <strong>investor storytelling.</strong>
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Reframed the deck to a bold problem statement, a
              <strong>visionary solution</strong> and a <strong>strategic edge</strong>.
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;"><strong>Simplified technical language</strong> without losing
              depth.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Used <strong>whitespace</strong> and <strong>visual
                pacing</strong> to enhance clarity and engagement.</li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">


          <p style="text-align: left;">
            With deep storytelling expertise gained during her time at McKinsey and later at Lightspeed, Victoria helped
            us move beyond academic framing and shape a compelling, investor-ready story with pitch-perfect slides. She
            guided us to structure the deck as a high-level narrative, moving from a bold problem statement to a
            visionary
            solution and strategic edge, all while emphasising visual clarity. We discussed how to simplify technical
            language without losing depth, reorder slides for greater impact, and use whitespace and pacing to hold
            attention. Her slide-by-slide feedback led us to rebuild our deck with thematic titles, more intuitive
            design,
            and a clearer value proposition for external partners.
            <br><br>
            The two meetings held with her fundamentally shifted our communication strategy, helping us transition from
            a
            lab-focused mindset to a high-conviction pitch aligned with industry and investor expectations. This
            foundation proved invaluable for our subsequent meetings with investors and partners.
          </p>
          <div class="collapsible-close  collapsible-close-grey">Close</div>
        </div>
      </div>
    </div>
  </div>



  <div id="nelli-morgulchik" class="two-column-container timeline-event timeline-event-grey"
    style="margin-top: -0.1rem;">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">
        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Nelli
            Morgulchik</span></div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/nelli1.webp" style="max-width: 70%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>



        <p style="text-align: left;">After refining our initial narrative, we met with Nelli Morgulchik, a biotech angel
          investor and co-founder of future.bio, a syndicate of builders and investors at the intersection of
          computation and biology.</p>


        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">


          <ul>
            <li style="text-align:left; color: white;">Aimed to refine our <strong>investor pitch deck</strong> and
              <strong>outreach strategy.</strong>
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Broke down milestones into <strong>short-term</strong> and
              <strong>long-term actionable stages</strong>.
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Shifted emphasis from alternative media to <strong>cultivated
                meat</strong> to increase appeal to investors and consumers.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">We later applied and tested improvements in our <strong>Jamboree
                presentation</strong>.</li>
          </ul>
        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">

          <p style="text-align: left;">
            As an ex-VC at Hummingbird Ventures, Nelli provided us with targeted feedback on both our pitch deck from a
            biotech investor lens and outreach strategy. She advised us to separate our investor pitch deck from
            fundraising materials, removing the latter completely as it blurred our value proposition. She highlighted
            the
            importance of including a pricing slide backed by competitor analysis to demonstrate cost advantage. Nelli
            also encouraged us to make our roadmap more transparent, breaking down short-term milestones and long-term
            vision into clear, actionable stages, which helped us further refine our deck and later our Jamboree
            presentation.
            <br><br>
            Beyond strategic input, she introduced us to key industry contacts at Multus and Hoxton Farms, helping us
            secure upcoming stakeholder interviews. Following this meeting, we restructured our deck, added a dedicated
            pricing slide, clarified our differentiation, and shifted our messaging to center more clearly on cultivated
            meat rather than media narratives. Her input was instrumental in aligning our investor-facing materials with
            real-world expectations and setting the foundation for our next wave of strategic conversations.
          </p>
          <div class="collapsible-close  collapsible-close-grey">Close</div>
        </div>
      </div>
    </div>
  </div>


  <div id="olivia-brown" class="two-column-container timeline-event timeline-event-grey" style="margin-top: -0.1rem;">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">
        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Olivia
            Brown</span>
        </div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/olivia1.webp" style="max-width: 70%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>


        <p style="text-align: left;">At two different points of our journey, we consulted Olivia Brown from
          Imperial
          Enterprise Lab to strengthen the entrepreneurial side of our project. Olivia specializes in startup
          acceleration and market strategy, and her guidance helped us bridge the gap between scientific innovation
          and
          business development.</p>


        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">


          <ul>
            <li style="text-align:left; color:white;">Aimed to <strong>strengthen</strong>
              <strong>entrepreneurial</strong> and
              <strong>business strategy.</strong>
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color:white;">Defined our <strong>customer base through ICP analysis
                and</strong>
              <strong>scalability</strong> potential.
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color:white;">Began market research journey through targeted stakeholder
              interviews &
              consumer surveys.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color:white;">Unlocked access to Expert Network and key relevant communities.
            </li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">


          <p style="text-align: left;">
            In our first meeting, early in the project, Olivia pushed us to think critically about our business edge.
            She
            asked us to define who our customers really are, how scalable our idea could be, and what branding choices
            would best convey our value to partners and investors. She highlighted the importance of market analysis and
            competitor mapping, and encouraged us to validate our assumptions by speaking directly with industry
            stakeholders.
            <br><br>
            To support this, she introduced us to a wide range of resources within Imperial and beyond, including the
            startup directory, Founder Slack, Hackspace, EIT Food, and the Food Student Research Network. These
            connections laid the foundation for our outreach and helped us test our positioning in the cultivated meat,
            media, and purification industries.
            <br><br>
            Later in our journey, Olivia worked with us again to refine our pitch. This time, her feedback focused on
            balance: ensuring that our presentation combined the rigor of science with the clarity of a strong business
            narrative. She urged us to broaden our framing beyond cultivated meat and highlight wider applications in
            vaccines and biomanufacturing, which positioned our work as a flexible platform technology rather than a
            single-industry bet. She also guided us through IP considerations and advised us on how best to engage with
            the Enterprise Lab’s Experts in Residence hub, offering access to over 100 specialists for targeted
            feedback.
            <br><br>
            Taken together, these two consultations reshaped our entrepreneurial approach. Olivia’s early guidance
            clarified our direction and outreach, while her later advice refined our communication and market
            positioning.
          </p>
          <div class="collapsible-close  collapsible-close-grey">Close</div>
        </div>
      </div>
    </div>
  </div>


  <div class="timeline-section-header header-grey" id="ip">
    <div class="tagline-subline"><span>Intellectual property</span></div>
  </div>

  <div id="katie-moruzzi" class="two-column-container timeline-event timeline-event-grey">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">

        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Katie
            Moruzzi</span>
        </div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/katie.webp" style="max-width: 70%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>


        <p style="text-align: left;">As students working on a project in a patent-heavy industry, we faced uncertainty
          around the legal pathways to bring our idea to market. We were constrained by both university research rules
          and international student visa laws, and unsure whether patents or trade secrets would be the most effective
          route.</p>


        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">


          <ul>
            <li style="text-align:left; color: white;">Aimed to refine our <strong>investor pitch deck</strong> and
              <strong>outreach strategy.</strong>
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Broke down milestones into <strong>short-term</strong> and
              <strong>long-term actionable stages</strong>.
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Shifted emphasis from alternative media to <strong>cultivated
                meat</strong> to increase appeal to investors and consumers.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">We later applied and tested improvements in our <strong>Jamboree
                presentation</strong>.</li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">


          <p style="text-align: left;">
            During our consultation with Katie Moruzzi, Imperial Expert-in-Residence and Associate at Briffa -
            Intellectual Property Lawyers, we learned about the five main categories of IP protection: trademarks,
            copyright, registered designs, patents, and confidential know-how. We also discussed the trade-offs between
            filing patents and relying on trade secrets. Patents can provide strong protection but are costly (around
            £5,000 per country), require public disclosure, and must be expanded internationally within a strict 6-month
            window. Trade secrets, by contrast, avoid disclosure and costs, but only work if the invention cannot be
            easily reverse-engineered.
            <br><br>
            Additionally, as yeast engineering is highly patented, we have to confirm novelty and freedom-to-operate
            before filing. We were advised to perform prior searches, check our names and logos against UK Companies
            House
            and IPO databases, and speak with SynBio-specialist patent attorneys, which we have immediately taken upon
            doing.
            <br><br>
            Another key complication we would encounter is company formation: as international students, we cannot
            immediately incorporate in the UK, which risks fragmenting ownership if IP is held individually, hence we
            had
            to look into alternative ways of incorporation.
          </p>
          <div class="collapsible-close  collapsible-close-grey">Close</div>
        </div>
      </div>
    </div>
  </div>


  <div id="sara-holland" class="two-column-container timeline-event timeline-event-grey" style="margin-top: -1%;">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">

        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Sara Holland</span>
        </div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/sara.webp" style="max-width: 70%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>


        <p style="text-align: left;">After our meeting with an IP lawyer, we continued our exploration of IP law by
          investigating patenting possibilities. We met with Sara Holland, Partner at Potter Clarkson, who specialises
          in biotechnology patents and has a track record of supporting iGEM teams. </p>


        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">


          <ul>
            <li style="text-align:left; color: white;">Consulted on <strong>patentability criteria</strong> <strong>and
                timeline</strong> considering iGEM deliverables</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Researched into the <strong>patentability and filing of our
                engineered constructs</strong>.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Confirmed <strong>feasibility of a short-term priority
                application</strong> to secure rights.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Ultimately <strong>reconfirmed our mission of advocating for open
                science.</strong></li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">




          <p style="text-align: left;">She briefed us on patentability
            criteria, specifically how unique gene knockout combinations could be patentable if they produce unexpected
            synergistic effects. We also discussed patenting practices across different jurisdictions, including the US,
            UK, and China. She recommended the European Patent Office as our primary patenting venue because it's more
            favorable than the US, particularly due to its narrower prior art rules. However, the filing timeline was
            identified as a major barrier: any patent application would need to be submitted well before iGEM deadlines,
            requiring a UK priority filing within days. While minimal preliminary data would suffice for an initial
            filing, the uncertainty around ownership with Imperial College complicated matters further, as Imperial
            could
            either retain ownership and cover costs, disclaim ownership and leave costs to us, or negotiate shared
            ownership. After considering these factors, and staying aligned with our commitment to open science, we
            decided not to pursue patent protection, ensuring our work remains accessible to future iGEM teams while
            focusing on immediate project impact.
          </p>
          <div class="collapsible-close  collapsible-close-grey">Close</div>
        </div>
      </div>
    </div>
  </div>


  <div class="timeline-section-header header-grey" id="simulating-a-biotech-investor-pitch">
    <div class="tagline-subline"><span>Simulating a Biotech Investor Pitch</span></div>
  </div>

  <div id="pedro-lovatt-garcia" class="two-column-container timeline-event timeline-event-grey">
    <div class="timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">

        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Dr. Pedro Lovatt
            Garcia</span></div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/pedro.webp" style="max-width: 70%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>


        <p style="text-align: left;">Dr. Pedro Lovatt Garcia is a Biotech Investment expert who played a key role in
          refining both the strategic direction and communication of Growf's pitch deck.</p>


        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">


          <ul>
            <li style="text-align:left; color: white;">Aimed to trial run <strong>pitch deck</strong> and
              <strong>strategy</strong> in light of <strong>cultivated meat market challenges.</strong>
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Encouraged reframing the <em>K. phaffii</em> platform as a
              <strong>versatile tool beyond cultivated meat.</strong>
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Shifted from specific cost figures to <strong>performance-based
                metrics.</strong></li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Re-evaluated <strong>go-to-market</strong> strategy in light of
              the cultivated meat market.</li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">


          <p style="text-align: left;"> With the cultivated meat
            industry facing significant challenges post-2022, such as rising interest rates, reduced venture funding,
            and
            an increase in acquisitions, he stressed the importance of adapting the narrative to address these shifts.
            Pedro encouraged the team to expand the focus of the K. phaffii platform, positioning it as a versatile tool
            for broader biomanufacturing applications, such as vaccine protein production. This reframing allowed the
            project to appeal to a wider range of industries and investors, especially those with more immediate needs.
            <br><br>
            His input led to important changes in the pitch deck, notably shifting from specific cost figures to broader
            performance metrics. Instead of quoting exact prices, Pedro recommended highlighting efficiency gains (e.g.,
            3x improvements), which provide a more credible and flexible narrative. He also advised revising technical
            terminology, using "protein secretion" to better convey the platform’s broader capabilities. In addition, he
            suggested removing speculative cost projections and focusing on efficiency data and potential savings to
            present a more grounded business case.
            <br><br>
            Pedro also guided the go-to-market strategy, recommending an initial focus on applications like vaccine
            manufacturing, where there’s clearer demand for protein expression tools. He emphasized the importance of
            identifying target customers and showcasing real or potential partnerships to strengthen traction. Finally,
            Pedro encouraged exploring the sale of strain IP as a short-term revenue model before developing proprietary
            growth factors. His contributions helped refine the project’s approach to both the market and investors,
            ensuring it was better aligned with the industry's current dynamics.
          </p>
          <div class="collapsible-close  collapsible-close-grey">Close</div>
        </div>
      </div>
    </div>
  </div>

  <div id="hugh-bowen" class="two-column-container timeline-event timeline-event-grey" style="margin-top: -0.1rem;">
    <div class=" timeline-dot"></div>
    <div class="column-left">
      <div class="timeline-content">

        <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Hugh Bowen</span>
        </div>
        <div class="image-aligner-center">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/hugh.webp" style="max-width: 70%;">
        </div>
      </div>
    </div>
    <div class="column-right">
      <div class="timeline-content">
        <div class="spacer5"></div>



        <p style="text-align: left;">Meeting with Hugh Bowen, Senior Investor at SOSV, provided invaluable insights into
          how to refine both our pitch and broader strategy.</p>


        <p style="text-align: left;">
          <italic>Discussion Points:</italic>
        </p>
        <div class="justify-left">


          <ul>
            <li style="text-align:left; color: white;">Aimed to gain <strong>investor-level feedback</strong> to refine
              our <strong>pitch</strong> and <strong>strategic positioning.</strong></li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;"><strong>Clarified core offering</strong>, leading to a
              <strong>focused value proposition</strong> around growth factors.
            </li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;"><strong>Practiced a clearer, more cohesive storytelling</strong>
              of impact and feasibility.</li>
            <div class="spacer"></div>
            <li style="text-align:left; color: white;">Developed a stronger <strong>stakeholder engagement</strong> and
              <strong>communication strategy.</strong>
            </li>
          </ul>

        </div>

        <div class="spacer"></div>

        <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>

        <div class="collapsible-content">



          <p style="text-align: left;">The session offered a firsthand experience of presenting an
            early-stage biotech idea to a seasoned investor, allowing us to receive direct feedback on key aspects like
            vision, technical feasibility, and market potential. Hugh's feedback particularly challenged us to clarify
            the
            long-term impact of our project, especially in the context of food and synthetic biology.
            <br><br>
            One of the most significant takeaways was the importance of a clear, focused narrative. Hugh asked us to
            pinpoint exactly what we were offering: Is it the cultivated meat, the growth factors, or the engineered
            chassis? This forced us to re-evaluate our messaging and ultimately narrow our focus to growth factors,
            applied specifically to cultivated meat. This shift helped simplify our value proposition, making it more
            tangible and aligned with market needs.
            <br><br>
            Beyond refining our pitch, this exercise also taught us critical lessons in designing future stakeholder
            engagements. Whether interacting with policymakers, startup accelerators, or other potential investors, we
            learned how to position our project more effectively and communicate its value. The session underscored the
            need for a clear, cohesive story that resonates with different audiences, helping us refine both our
            approach
            to future pitches and how we position ourselves within the broader biotech ecosystem.
          </p>
          <div class="collapsible-close  collapsible-close-grey">Close</div>
        </div>
      </div>
    </div>
  </div>


  <div class="spacer3"></div>

</div>


<div class="page-section width-75" id="intro">

  <div class="section-title ">
    <h1 style="text-align: left;" class="animate-text-scramble">Integrated Human Practices Award Consideration</h1>
  </div>

  <p style="text-align: left;">
    Through our Human Practices work, we have shown that our project goes beyond scientific research and contributes to
    public wellbeing by addressing:
  </p>
  <div class="spacer2"></div>
  <ul>
    <li style="text-align:left;"><strong>Responsibility and positive impact for the world: We directly addressed
        sustainability, accessibility, and ethical considerations.</strong> Our conversations with Reka Tron and Martin
      at Hoxton Farms were central for that.</li>
    <div class="spacer"></div>
    <li style="text-align:left;"><strong>Integration throughout the entire project lifecycle:</strong> by
      <strong>consulting stakeholders whenever we faced a design or strategic decision</strong>, and adapting our work
      in response, summarised in the main <strong>Discussion Points</strong> section of each conversation.
    </li>
    <div class="spacer"></div>
    <li style="text-align:left;"><strong>Thorough implementation:</strong> We have done so with clear context and
      rationale, by <strong>identifying the specific expertise we needed at each stage</strong>. Dr. Brigitte Gasser’s
      help is a great example, being a pioneering figure in <em>K. phaffii</em> engineering.</li>
    <div class="spacer"></div>
    <li style="text-align:left;"><strong>Incorporation of diverse views:</strong> We made sure to <strong>incorporate
        views of those sceptical of the future of our target segment</strong> to best address their concerns. This was a
      guiding principle in reaching out to experts in academia, up-and-coming founders, established industry players,
      VCs, lawyers, and academics, to ensure our design reflected multiple perspectives.</li>
    <div class="spacer"></div>
    <li style="text-align:left;"><strong>Thorough documentation of strategy:</strong> Key takeaways, and especially
      disagreements were integrated comprehensively so that future teams can use our learnings as inspiration,
      <strong>presenting a transparent record of our reasoning and outcomes</strong>.
    </li>
  </ul>
  <div class="spacer"></div>
  <p style="text-align: left;">
    Finally, by showing how Human Practices can fundamentally reshape a project, we hope we have created an inspiring
    example for future iGEM teams of <strong>how academia and industry outreach can be integrated in a way that sets
      realistic standards for the commercial implementation of synthetic biology technologies.</strong>
  </p>

</div>


<div class="spacer3"></div>

<div class="citation-block" id="citations">
  <h3>References</h3>
  <ol>
    <li>
      E. Swartz, “Cell culture media and growth factor trends in the cultivated meat industry,” The Good Food
      Institute, 2021.
    </li>
  </ol>
</div>

{% endblock %}